26367-1-AP

antibody from Proteintech Group

Targeting: RBCK1 C20orf18, HOIL1, RBCK2, RNF54, UBCE7IP3, XAP4, ZRANB4

ELISA (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

26367-1-AP

Provider

Proteintech Group

Product name

RBCK1 antibody

Antibody type

Polyclonal

Description

KD/KO validated RBCK1 antibody (Cat. #26367-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Comprehensive analysis of PANoptosis-related molecular subtypes and prognostic model development of clear cell renal cell carcinoma.

Zhou P, Xu Z, Gan W, Jin X
Discover oncology 2026 Feb 6;17(1)

---

Novel Compound Heterozygous Mutations in HOIP Result in Autoinflammation and Immunodeficiency.

Wang L, Xiao J, Gan R, Tang X, Wu J
Journal of clinical immunology 2025 Sep 30;45(1):135

---

STING induces HOIP-mediated synthesis of M1 ubiquitin chains to stimulate NF-κB signaling.

Fischer TD, Bunker EN, Zhu PP, Le Guerroué F, Hadjian M, Dominguez-Martin E, Scavone F, Cohen R, Yao T, Wang Y, Werner A, Youle RJ
The EMBO journal 2025 Jan;44(1):141-165

---

The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis.

Wang Y, Peng M, Zhong Y, Xiong W, Zhu L, Jin X
Oncogene 2023 Mar;42(13):952-966

---

Mechanistic insights into the homo-dimerization of HOIL-1L and SHARPIN.

Zhang Y, Xu X, Wang Y, Wang Y, Zhou X, Pan L
Biochemical and biophysical research communications 2023 Dec 31;689:149239

---

Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma.

Fu L, Bao J, Li J, Li Q, Lin H, Zhou Y, Li J, Yan Y, Langston ME, Sun T, Guo S, Zhou X, Chen Y, Liu Y, Zhao Y, Lu J, Huang Y, Chen W, Chung BI, Luo J
Frontiers in immunology 2022;13:1021935

---

RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.

Li Z, Su P, Ding Y, Gao H, Yang H, Li X, Yang X, Xia Y, Zhang C, Fu M, Wang D, Zhang Y, Zhuo S, Zhu J, Zhuang T
Cell communication and signaling : CCS 2022 Oct 24;20(1):164

---

Regulation of PTEN and ovarian cancer progression by an E3 ubiquitin ligase RBCK1.

Wang G, Zhuang Z, Shen S, Yang F, Jiang Z, Liu Z, Wang T, Hua L
Human cell 2022 May;35(3):896-908

---

RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling.

Niu Z, Fan J, Chen F, Yang H, Li X, Zhuang T, Guo C, Cao Q, Zhu J, Wang H, Huang Q
Cell death & disease 2022 Dec 6;13(12):1023

---

Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.

Chen L, Wang N, Hu W, Yu X, Yang R, Han Y, Yan Y, Nian N, Sha C
BMC musculoskeletal disorders 2021 Jan 7;22(1):35

---

A novel inhibitor of nuclear factor kappa-B kinase subunit gamma mutation identified in an incontinentia pigmenti patient with syndromic tooth agenesis.

Sun S, Li F, Liu Y, Qu H, Wong SW, Zeng L, Yu M, Feng H, Liu H, Han D
Archives of oral biology 2019 May;101:100-107

---

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.

Yu S, Dai J, Ma M, Xu T, Kong Y, Cui C, Chi Z, Si L, Tang H, Yang L, Sheng X, Guo J
Cell death & disease 2019 Mar 15;10(4):254